Finding and drugging the vulnerabilities of RAS-dependent cancers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

1. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.Journal of molecular biology · 2018
   Review
2. Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.Oncotarget · 2017
   Article
3. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.eLife · 2015
   Article
4. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities.Frontiers in physiology · 2014
   Review
5. Targeting the LKB1 tumor suppressor.Current drug targets · 2014
   Review
6. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2011
   Article
7. Harnessing synthetic lethal interactions in anticancer drug discovery.Nature reviews. Drug discovery · 2011
   Review
8. KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.Genes & cancer · 2011
   Article
9. Synthetic Lethality Induced by Loss of PKC δ and Mutated Ras.Genes & cancer · 2010
   Article
10. Converting cancer mutations into therapeutic opportunities.EMBO molecular medicine · 2009
    Article

Corrections and comments

• Comment on
  Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.2009
• Comment on
  A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.2009

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as